Glomerulonefritis en niños y jóvenes

Referencias

1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011;31(4):341–348 Google ScholarCrossref PubMed

2. Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 2017;32(1):43–57 Google ScholarCrossref PubMed

3. Lu DF, Moon M, Lanning LD, McCarthy AM, Smith RJ. Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol. 2012;27(5):773–781 Google ScholarCrossref PubMed

4. Michels M, Wijnsma KL, Kurvers RAJ, et al. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort. Pediatr Nephrol. 2022;37(3):601–612 Google ScholarCrossref PubMed

5. Dowsett T, Oni L. Anti-glomerular basement membrane disease in children: a brief overview. Pediatr Nephrol. 2022;37(8):1713–1719 Google ScholarCrossref PubMed

6. Plumb LA, Oni L, Marks SD, Tullus K. Paediatric anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: an update on renal management. Pediatr Nephrol. 2018;33(1):25–39 Google ScholarCrossref PubMed

7. Calatroni M, Consonni F, Allinovi M, et al. Prognostic factors and long-term outcome with ANCA-associated kidney vasculitis in childhood. Clin J Am Soc Nephrol. 2021;16(7):1043–1051

Google ScholarCrossref PubMed

8. Hirano D, Ishikawa T, Inaba A, et al. Epidemiology and clinical features of childhood-onset anti-neutrophil cytoplasmic antibody-associated vasculitis: a clinicopathological analysis. Pediatr Nephrol. 2019;34(8):1425–1433 Google ScholarCrossref PubMed

9. Sacri AS, Chambaraud T, Ranchin B, et al. Clinical characteristics and outcomes of childhood-onset ANCA-associated vasculitis: a French nationwide study. Nephrol Dial Transplant. 2015;30(suppl 1):i104–i112 Google ScholarPubMed

10. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol. 2010;6(9):538–546 Google ScholarCrossref PubMed

11. Hiraki LT, Benseler SM, Tyrrell PN, Hebert D, Harvey E, Silverman ED. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study. J Pediatr. 2008;152(4):550–556 Google ScholarCrossref PubMed

12. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. 2011;20(11):1187–1192 Google ScholarCrossref PubMed

13. Hiraki LT, Feldman CH, Liu J, et al. Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population. Arthritis Rheum. 2012;64(8):2669–2676 Google ScholarCrossref PubMed

14. Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542–1550 Google ScholarCrossref PubMed

15. Watson L, Leone V, Pilkington C, et al; UK Juvenile-Onset Systemic Lupus Erythematosus Study Group. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012;64(7):2356–2365 Google ScholarCrossref PubMed

16. Vazzana KM, Daga A, Goilav B, et al; CARRA Registry investigators. Principles of pediatric lupus nephritis in a prospective contemporary multi-center cohort. Lupus. 2021;30(10):1660–1670 Google ScholarCrossref PubMed

17. Smith EMD, Yin P, Jorgensen AL, Beresford MW. Clinical predictors of active LN development in children: evidence from the UK JSLE Cohort Study. Lupus. 2018;27(13):2020–2028

Google ScholarCrossref PubMed

18. Tarr T, Dérfalvi B, Győri N, et al. Similarities and differences between pediatric and adult patients with systemic lupus erythematosus. Lupus. 2015;24(8):796–803

Google ScholarCrossref PubMed

19. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–562

Google ScholarCrossref PubMed

20. Livingston B, Bonner A, Pope J. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus. 2011;20(13):1345–1355

Google ScholarCrossref PubMed

21. Joo YB, Park SY, Won S, Bae SC. Differences in clinical features and mortality between childhood-onset and adult-onset systemic lupus erythematosus: a prospective single-center study. J Rheumatol. 2016;43(8):1490–1497

Google ScholarCrossref PubMed

22. Pinheiro SVB, Dias RF, Fabiano RCG, Araujo SA, Silva ACSE. Pediatric lupus nephritis. J Bras Nefrol. 2019;41(2):252–265

Google ScholarCrossref PubMed

23. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6(1):7

Google ScholarCrossref PubMed

24. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039

Google ScholarCrossref PubMed

25. Bruschi M, Galetti M, Sinico RA, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol. 2015;26(8):1905–1924

Google ScholarCrossref PubMed

26. Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity. 2011;44(5):373–383

Google ScholarCrossref PubMed

27. Kalaaji M, Mortensen E, Jørgensen L, Olsen R, Rekvig OP. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol. 2006;168(6):1779–1792

Google ScholarCrossref PubMed

28. Flores-Mendoza G, Sansón SP, Rodríguez-Castro S, Crispín JC, Rosetti F. Mechanisms of tissue injury in lupus nephritis. Trends Mol Med. 2018;24(4):364–378

Google ScholarCrossref PubMed

29. Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther. 2011;13(6):250

Google ScholarCrossref PubMed

30. Mayadas TN, Rosetti F, Ernandez T, Sethi S. Neutrophils: game changers in glomerulonephritis? Trends Mol Med. 2010;16(8):368–378

Google ScholarCrossref PubMed

31. Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014;20(7):1126–1167

Google ScholarCrossref PubMed

32. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271–1277

Google ScholarCrossref PubMed

33. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686

Google ScholarCrossref PubMed

34. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159

Google ScholarCrossref PubMed

35. Wenderfer SE, Eldin KW. Lupus nephritis. Pediatr Clin North Am. 2019;66(1):87–99

Google ScholarCrossref PubMed

36. Groot N, de Graeff N, Marks SD, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76(12):1965–1973

Google ScholarCrossref PubMed

37. Sule SD, Moodalbail DG, Burnham J, Fivush B, Furth SL. Predictors of kidney disease in a cohort of pediatric patients with lupus. Lupus. 2015;24(8):862–868

Google ScholarCrossref PubMed

38. Thakur N, Rai N, Batra P. Pediatric lupus nephritis: review of literature. Curr Rheumatol Rev. 2017;13(1):29–36

Google ScholarCrossref PubMed

39. Weening JJ, D’Agati VD, Schwartz MM, et al; International Society of Nephrology Working Group on the Classification of Lupus Nephritis; Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521–530

Google ScholarCrossref PubMed

40. Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789–796

Google ScholarCrossref PubMed

41. Scobell R, Pradhan M. Management of lupus nephritis in children. Indian Pediatr. 2020;57(5):401–406

Google ScholarCrossref PubMed

42. Dall’Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305–1313

Google ScholarCrossref PubMed

43. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713–723

Google ScholarCrossref PubMed

44. Tamirou F, D’Cruz D, Sangle S, et al; MAINTAIN Nephritis Trial Group. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016;75(3):526–531

Google ScholarCrossref PubMed

45. Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4):753–779

Google ScholarCrossref PubMed

46. Lau KK, Ault BH, Jones DP, Butani L. Induction therapy for pediatric focal proliferative lupus nephritis: cyclophosphamide versus mycophenolate mofetil. J Pediatr Health Care. 2008;22(5):282–288

Google ScholarCrossref PubMed

47. Buratti S, Szer IS, Spencer CH, Bartosh S, Reiff A. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol. 2001;28(9):2103–2108

Google ScholarPubMed

48. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61–64

Google ScholarCrossref PubMed

49. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922

Google ScholarPubMed

50. Mina R, von Scheven E, Ardoin SP, et al; Carra SLE Subcommittee. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–383

Google ScholarCrossref PubMed

51. Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap HK. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010;19(8):965–973

Google ScholarCrossref PubMed

52. Baskin E, Ozen S, Cakar N, Bayrakci US, Demirkaya E, Bakkaloglu A. The use of low-dose cyclophosphamide followed by AZA/MMF treatment in childhood lupus nephritis. Pediatr Nephrol. 2010;25(1):111–117

Google ScholarCrossref PubMed

53. Wenderfer SE, Ruth NM, Brunner HI. Advances in the care of children with lupus nephritis. Pediatr Res. 2017;81(3):406–414

Google ScholarCrossref PubMed

54. Willems M, Haddad E, Niaudet P, et al; French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr. 2006;148(5):623–627

Google ScholarCrossref PubMed

55. Lehman TJ, Singh C, Ramanathan A, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J. 2014;12:3

Google ScholarCrossref PubMed

56. Watson L, Beresford MW, Maynes C, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus. 2015;24(1):10–17

Google ScholarCrossref PubMed

57. Tambralli A, Beukelman T, Cron RQ, Stoll ML. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42(3):541–546

Google ScholarCrossref PubMed

58. Tse KC, Li FK, Tang S, Tang CS, Lai KN, Chan TM. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Lupus. 2005;14(12):947–952

Google ScholarCrossref PubMed

59. Kanda H, Kubo K, Tateishi S, et al. Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus. 2005;14(4):288–292

Google ScholarCrossref PubMed

60. Hahn BH, McMahon MA, Wilkinson A, et al; American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808

Google ScholarCrossref PubMed

61. Mok CC, Tse SM, Chan KL, Ho LY. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus. 2018;27(5):722–727

Google ScholarCrossref PubMed

62. Bertsias GK, Tektonidou M, Amoura Z, et al; European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782

Google ScholarCrossref PubMed

63. Alarcón GS, McGwin G, Bertoli AM, et al; LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66(9):1168–1172

Google ScholarCrossref PubMed

64. Sisó A, Ramos-Casals M, Bové A, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus. 2008;17(4):281–288

Google ScholarCrossref PubMed

65. Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6(9):2192–2199

Google ScholarCrossref PubMed

66. Hiraki LT, Lu B, Alexander SR, et al. End-stage renal disease due to lupus nephritis among children in the US, 1995–2006. Arthritis Rheum. 2011;63(7):1988–1997

Google ScholarCrossref PubMed

67. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol. 2007;22(2):222–231

Google ScholarCrossref PubMed

68. Rianthavorn P, Buddhasri A. Long-term renal outcomes of childhood-onset global and segmental diffuse proliferative lupus nephritis. Pediatr Nephrol. 2015;30(11):1969–1976

Google ScholarCrossref PubMed

69. Marks SD, Sebire NJ, Pilkington C, Tullus K. Clinicopathological correlations of paediatric lupus nephritis. Pediatr Nephrol. 2007;22(1):77–83

Google ScholarCrossref PubMed

70. Freedman BI, Langefeld CD, Andringa KK, et al; Lupus Nephritis–End-Stage Renal Disease Consortium. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014;66(2):390–396

Google ScholarCrossref PubMed

71. Gibson KL, Gipson DS, Massengill SA, et al. Predictors of relapse and end stage kidney disease in proliferative lupus nephritis: focus on children, adolescents, and young adults. Clin J Am Soc Nephrol. 2009;4(12):1962–1967

Google ScholarCrossref PubMed

72. Lopes SRM, Gormezano NWS, Gomes RC, et al; Brazilian Childhood-onset Systemic Lupus Erythematosus Group. Outcomes of 847 childhood-onset systemic lupus erythematosus patients in three age groups. Lupus. 2017;26(9):996–1001

Google ScholarCrossref PubMed

73. Gipson DS, Ferris ME, Dooley MA, Huang K, Hogan SL. Renal transplantation in children with lupus nephritis. Am J Kidney Dis. 2003;41(2):455–463

Google ScholarCrossref PubMed

74. Trindade VC, Carneiro-Sampaio M, Bonfa E, Silva CA. An update on the management of childhood-onset systemic lupus erythematosus. Paediatr Drugs. 2021;23(4):331–347

Google ScholarCrossref PubMed

75. Ferreira JCOA, Trindade VC, Espada G, et al. Epidemiology and management practices for childhood-onset systemic lupus erythematosus patients: a survey in Latin America. Clin Rheumatol. 2018;37(12):3299–3307

Google ScholarCrossref PubMed

76. Sprangers B, Monahan M, Appel GB. Diagnosis and treatment of lupus nephritis flares: an update. Nat Rev Nephrol. 2012;8(12):709–717

Google ScholarCrossref PubMed

77. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–2557

Google ScholarCrossref PubMed

78. Coppo R, Robert T. IgA nephropathy in children and in adults: two separate entities or the same disease? J Nephrol. 2020;33(6):1219–1229

Google ScholarCrossref PubMed

79. Barbour SJ, Coppo R, Er L, et al; International IgA Nephropathy Network. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99(6):1439–1450

Google ScholarCrossref PubMed

80. Coppo R. Pediatric IgA nephropathy in Europe. Kidney Dis. 2019;5(3):182–188

Google ScholarCrossref  

81. Coppo R, Gianoglio B, Porcellini MG, Maringhini S; Group of Renal Immunopathology of the Italian Society of Pediatric Nephrology and Group of Renal Immunopathology of the Italian Society of Nephrology. Frequency of renal diseases and clinical indications for renal biopsy in children (report of the Italian National Registry of Renal Biopsies in Children). Nephrol Dial Transplant. 1998;13(2):293–297

Google ScholarCrossref PubMed

82. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402–2414

Google ScholarCrossref PubMed

83. Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686

Google ScholarCrossref PubMed

84. Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–989

Google ScholarCrossref PubMed

85. Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795–1803

Google ScholarCrossref PubMed

86. Allen AC, Harper SJ, Feehally J. Galactosylation of N- and O-linked carbohydrate moieties of IgA1 and IgG in IgA nephropathy. Clin Exp Immunol. 1995;100(3):470–474